An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC) - A3907-002

Albireo AB0 个研究点目标入组 25 人开始时间: 2022年8月25日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Albireo AB
入组人数: 25

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 64（—）
性别: All

入选标准

•1. Adults between 18 and 75 years of age (inclusive). 2. Have a clinical diagnosis of large-duct PSC with evidence of more than 6 months duration with either a consistent magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing cholangitis and historical evidence of elevated alkaline phosphatase (ALP). 3. Willing to sign informed consent. 4. Women of childbearing potential (WOCBP) and males with female partners of childbearing potential must agree to use contraception as detailed in Section 9.3.18. Women of nonchildbearing potential (WONCBP) must meet the definition in Section 9.3.18 and have a confirmatory follicle stimulating hormone [FSH] level = 40 mIU/mL . 5. Alkaline Phosphatase (ALP) value > 1.5 × upper limit of normal (ULN) but = 10 ×ULN at Visit 1 (Screening Period). Before starting 12 weeks treatment variability of < 30% between ALP values at Visit 1 and Visit 2 must be confirmed. If variability is > 30 % a third ALP value may be obtained. If the third ALP value meets >1.5 × ULN but = 10 × ULN the patient can start the 12-week treatment period. 6. Arms 1-3 Only: Total bilirubin < 1.5 × ULN (unless due to Gilberts Syndrome or hemolysis) and normal direct bilirubin. 7. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 5 × ULN 8. Serum bile acid level > ULN 9. Arms 1 - 3 Only: An MRCP or equivalent imaging modality performed within 6 months before the Screening Period that is consistent with PSC without a clinically relevant stricture. 10. Arm 4 Only: An MRCP or equivalent imaging modality performed within 6 months before the Screening Period that is consistent with PSC with a clinically relevant stricture, or clinically relevant bile duct obstruction (see Inclusion # 12 for additional information). 11. Use of ursodeoxycholic acid (UDCA) with a total daily dose = 23 mg/kg/day, or bile acid-binding resins are permitted, with a minimum of 3 months of stable treatment prior to the Screening Period, and expected to remain on a stable dose through the 12-week treatment period; or a minimum of 3 months off UDCA prior to the Screening Period if UDCA was recently discontinued. 12. If a patient has inflammatory bowel disease (IBD) with a minimum disease duration of 4 weeks, this diagnosis should be documented. Inflammatory bowel disease should be in clinical remission or mildly active according to Crohn’s Disease Activity Index (CDAI), partial Mayo score for Crohn’s Disease (CD) and ulcerative colitis (UC), respectively (i.e., patients with CDAI score < 220 and Mayo score < 5, respectively). Patients with IBD should have had a colonoscopy performed within one year prior to the Screening Period with results showing no evidence of dysplasia or cancer., 13. Clinically stable for at least 3 months prior to the Screening Period. 14. Arm 4 Only: One stable clinically relevant biliary stricture of at least 4 weeks duration on contrast enhanced MRI/MRCP with > 75% reduction of duct diameter in the common bile duct or hepatic duct without suspicion of cholangiocarcinoma (further established by imaging and stable CA 19-9 below ULN repeated twice over 1 month), or cholelithiasis. Subjects may have signs or symptoms of worsening obstructive cholestasis (increasing jaundice, nausea, anorexia, steatorrhea and worsening or new onset pruritus), deterioration of liver function (i.e., decreasing platelet count, increasing international norm

排除标准

•Medical History - 1. Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis, recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis, surgical or blunt abdominal trauma, recurrent pyogenic cholangitis, choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other cause of secondary sclerosing cholangitis). 2. Biliary intervention within 3 months prior to study enrollment or planned. 3. Presence of alternative causes of chronic liver disease, including alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune hepatitis, or active hepatitis B or C. 4. IBD with uncontrolled moderate to severe activity and/or on treatment with any immunosuppressive, immunomodulator, or biologic agent for treatment of IBD (i.e. azathioprine, 6 mercaptopurine, tacrolimus, methotrexate, infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, ozanimod). Treatment with corticosteroids (including budesonide, budesonide MMX and beclomethasone) in the previous 4 weeks. 5. History of human immunodeficiency virus infection or any other known relevant infection (e.g., tuberculosis). 6. History of colostomy or colectomy. 7. History of malignancy, including hepatocellular carcinoma within the past 10 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 8. History of transplants, including liver transplantation, or currently on active transplantation list. 9. Current or a history of ascites, encephalopathy, or history of esophageal variceal bleeding. 10. Known or suspected overlapping clinical and histologic diagnosis of autoimmune hepatitis. 11. Small duct PSC (evidence of PSC on historical liver histology, with normal bile ducts on cholangiography). 12. Liver cirrhosis as assessed by any of the following: a. historical liver histology • suspected liver fibrosis, defined by liver stiffness measurement, assessed by FibroScan (FibroScan value > 14.4 kPa). b. signs and symptoms of hepatic decompensation (including, but not limited to, jaundice, ascites, variceal haemorrhage, and/or hepatic encephalopathy). 13. Are female of childbearing potential, including those who are pregnant or lactating 14. History of alcohol or substance abuse in the previous 2 years. Patients must agree to refrain from illicit drug (including marijuana) and alcohol use during the study 15. Hypersensitivity to investigational medicinal product (A3907) and excipients. 16. Presence of any contraindication for undergoing MRCP (e.g., pacemaker). Treatment - 17. Administration of medications that slow gastrointestinal motility (Section 8.6.2). 18. Treatment with rifampicin 19. Treatment with CYP3A4 substrates acetaminophen, codeine, ciclosporin (cyclosporin), diazepam, and erythromycin. 20. Treatment with vitamin D or fibrates, unless patient is on a stable dose = 6 months prior to baseline. 21. Exposure to an investigational drug, biologic agent, or medical device within 30 days prior to Screening, or 5 half-lives of the study agent, whichever is longer. Laboratory Exclusions - 22. Platelet count < 150 000/mm3. 23. Albumin level < 3.0 g/dL. 24. International normalised ratio (INR) > 1.4 (the patient may be treated with vitamin K intravenously, and if INR is = 1.4 at resampling, the patient may be enrolled). 25. Advanced renal disease (glomerular filtration rate [GFR] < 70 mL/min/1.73 m2 ) Misc

研究者

发起方

Albireo AB

相似试验

进行中（未招募）

1 期

A study to determine if GBT440 can increase the level of oxygen in the blood of people with Idiopathic Pulmonary Fibrosis (IPF) who need to use supplemental oxygen when resting.Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

EUCTR2017-001276-27-GBGlobal Blood Therapeutics Inc.32

进行中（未招募）

1 期

Study to Evaluate how safe and how effective is CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell LymphomaPatients With Relapsed/Refractory MYC-Altered Diffuse Large B-Cell LymphomaMedDRA version: 19.0 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-004509-34-FRCuris, Inc.120

进行中（未招募）

1 期

Study to Evaluate how safe and how effective is CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC AlterationsPatients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma including patients with MYC alterationsMedDRA version: 19.1 Level: PT Classification code 10012821 Term: Diffuse large B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-004509-34-NLCuris, Inc.200

撤回

2 期

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC AlterationsLymphoma

NL-OMON46260Curis, Inc.10

进行中（未招募）

1 期

EUCTR2014-004509-34-ESCuris, Inc.120